Can trastuzumab be effective against tumors with low HER2/Neu (ErbB2) receptors?

Journal of Clinical Oncology

Volumn 24, Issue 23, 2006, Pages 3722-3725

  Arteaga, Carlos L ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; NEU DIFFERENTIATION FACTOR; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SENSITIVITY; EDITORIAL; ENZYME ACTIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; BREAST TUMOR; DRUG EFFECT; DRUG RESISTANCE; FEMALE; GENETICS; METABOLISM; NOTE; PHOSPHORYLATION; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEUREGULIN-1; PHOSPHORYLATION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-2;

EID: 33747348728     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.5268     Document Type: Editorial

References (44)

1. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137, 2001
2. Graus-Porta D, Beerli RR, Daly JM, et al: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. Embo J 16:1647-1655, 1997
3. Pinkas-Kramarski R, Soussan L, Waterman H, et al: Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. Embo J 15:2452-2467, 1996
4. Wang LM, Kuo A, Alimandi M, et al: ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB4. Proc Natl Acad Sci U S A 95:6809-6814, 1998
5. Worthylake R, Opresko LK, Wiley HS: ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem 274:8865-8874, 1999
6. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
7. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
8. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002
9. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005
10. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005
11. Alimandi M, Romano A, Curia MC, et al: Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10:1813-1821, 1995
12. Yakes FM, Chinratanalab W, Ritter CA, et al: Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62:4132-4141, 2002
13. Thor AD, Liu S, Edgerton S, et al: Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): A study of incidence and correlation with outcome in breast cancer. J Clin Oncol 18:3230-3239, 2000
14. Samanta A, LeVea CM, Dougall WC, et al: Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation. Proc Natl Acad Sci U S A 91:1711-1715, 1994
15. Muller WJ, Arteaga CL, Muthuswamy SK, et al: Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice. Mol Cell Biol 16:5726-5736, 1996
16. DiGiovanna MP, Stern DF, Edgerton SM, et al: Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 23:1152-1160, 2005
17. Hirsch FR, Varella-Garcia M, Franklin WA, et al: Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer 86:1449-1456, 2002
18. Cappuzzo F, Varella-Garcia M, Shigematsu H, et al: Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol 23:5007-5018, 2005
19. Naidu R, Yadav M, Nair S, et al: Expression of c-erbB3 protein in primary breast carcinomas. Br J Cancer 78:1385-1390, 1998
20. Gasparini G, Gullick WJ, Maluta S, et al: C-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma: An immunocytochemical study. Eur J Cancer 1:16-22, 1994
21. Quinn CM, Ostrowski JL, Lane SA, et al: C-erbB-3 protein expression in human breast cancer: Comparison with other tumour variables and survival. Histopathology 25:247-252, 1994
22. Travis A, Pinder SE, Robertson JF, et al: C-erbB-3 in human breast carcinoma: Expression and relation to prognosis and established prognostic indicators. Br J Cancer 74:229-233, 1996
23. Bobrow LG, Millis RR, Happerfield LC, et al: C-erbB-3 protein expression in ductal carcinoma in situ of the breast. Eur J Cancer 33:1846-1850, 1997
24. Wallasch C, Weiss FU, Niederfellner G, et al: Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. Embo J 14:4267-1275, 1995
25. Fedi P, Pierce JH, di Fiore PP, et al: Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB- 3 signaling from that of other ErbB/EGFR family members. Mol Cell Biol 14:492-500, 1994
26. Holbro T, Beerli RR, Maurer F, et al: The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A 100:8933-8938, 2003
27. Webster MA, Hutchinson JN, Rauh MJ, et al: Requirement for both Shc and phosphatidylinositol 3′' kinase signaling pathways in polyomavirus middle T-mediated mammary tumorigenesis. Mol Cell Biol 18:2344-2359, 1998
28. Siegel PM, Ryan ED, Cardiff RD, et al: Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: Implications for human breast cancer. Embo J 18:2149-2164, 1999
29. Moulder SL, Yakes FM, Muthuswamy SK, et al: Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61:8887-8895, 2001
30. Lane HA, Beuvink I, Motoyama AB, et al: ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: Receptor overexpression does not determine growth dependency. Mol Cell Biol 20:3210-3223, 2000
31. Smith BL, Chin D, Maltzman W, et al: The efficacy of herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins. Br J Cancer 91:1190-1194, 2004
32. Agus DB, Akita RW, Fox WD, et al: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2:127-137, 2002
33. Cho HS, Mason K, Ramyar KX, et al: Structure of the extracellular region of HER2 alone and in complex with the herceptin Fab. Nature 421:756-760, 2003
34. Franklin MC, Carey KD, Vajdos FF, et al: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5:317-328, 2004
35. Valabrega G, Montemurro F, Sarotto I, et al: TGFalpha expression impairs Trastuzumab-induced HER2 downregulation. Oncogene 24:3002-3010, 2005
36. Menendez JA, Mehmi I, Lupu R: Trastuzumab in combination with heregulin-activated HER-2/neu (erbB2) triggers a receptor-enhanced chemosensitivity (REC) effect in the absence of HER2/neu overexpression. J Clin Oncol 3735-3746, 2006
37. Yuste L, Montero JC, Esparis-Ogando A, et al: Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin. Cancer Res 65:6801-6810, 2005
38. Tang CK, Perez C, Grunt T, et al: Involvement of heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast cancer cells. Cancer Res 56:3350-3358, 1996
39. Krane IM, Leder P: NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. Oncogene 12:1781-1788, 1996
40. Atlas E, Cardillo M, Mehmi I, et al: Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo. Mol Cancer Res 1:165-175, 2003
41. Rubin BP, Schuetze SM, Eary JF, et al: Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 20:3586-3591, 2002
42. Scher HI, Sarkis A, Reuter V, et al: Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin Cancer Res 1:545-550, 1995
43. Grandis JR, Melhem MF, Gooding WE, et al: Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90:824-832, 1998
44. Trigo J, Hitt R, Koralewski P, et al: Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of phase II study. Proc Am Soc Clin Oncol 22:487, 2004 (abstr 5502)